Radcliffe Cardiology, Jordan Rance; Special Editor: Greg Guillory

Broadcast

Clone of The New Era in AF Screening at Home

Prof Dr Gregory YH Lip, Prof Dr med Bernd Sanner, Assoc Prof Keitaroo Senoo, et al

About

Heart failure (HF) is a rapidly growing public health issue with an estimated prevalence of >37.7 million individuals globally. HF is a shared chronic phase of cardiac functional impairment secondary to many aetiologies, and patients with HF experience a range of symptoms that affect their quality of life, including dyspnoea, fatigue, poor exercise tolerance and fluid retention.

The burden of HF will continue to rise, due to population aging, population growth and improved treatment of HF and other cardiovascular disorders. As a result, clinicians will be increasingly challenged to develop treatment plans and care systems that reduce the high levels of morbidity and mortality experienced by these patients, both from their HF and other comorbidities.

Articles

Corrigendum to: Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments

Citation:

European Cardiology Review 2019;14(3):201

Destination Therapy with LVAD in Non-transplant Centres

Published:

27 April 2020

Citation:

European Cardiology Review 2020;15:e19.

Novel Aspects of Classification, Prognosis and Therapy in Takotsubo Syndrome

Citation:

European Cardiology Review 2019;14(3):191–6

Artificial Intelligence, Data Sensors and Interconnectivity: Future Opportunities for Heart Failure

Citation:

Cardiac Failure Review 2020;6:e11.